Evidence map›Paper›PMID 36332629›Full record

ArticleStem cell reports2022

Notch activation during early mesoderm induction modulates emergence of the T/NK cell lineage from human iPSCs.

Dar Heinze, Seonmi Park, Andrew McCracken, Mona Haratianfar, Jonathan Lindstrom, Carlos Villacorta-Martin, Aditya Mithal, Feiya Wang, Meng Wei Yang, George Murphy and 1 more

Abstract read
In one paragraph

Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Generation of effector CD4Stem cell reports · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. iScience · 2023
    Article
  6. American journal of respiratory and critical care medicine · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Dar HeinzeCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA; Department of Surgery, Boston University Medical Center, Boston, MA, USA.
Seonmi ParkCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Andrew McCrackenCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Mona HaratianfarCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Jonathan LindstromCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Carlos Villacorta-MartinCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Aditya MithalCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Feiya WangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Meng Wei YangCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
George MurphyCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA.
Gustavo MostoslavskyCenter for Regenerative Medicine of Boston University and Boston Medical Center, Boston, MA, USA; Department of Medicine, Section of Gastroenterology at Boston University and Boston Medical Center, Boston, MA, USA. Electronic address: gmostosl@bu.edu.

Funding

NATIONAL BIOREPOSITORY OF LUNG DISEASE-SPECIFIC HUMAN INDUCED PLURIPOTENT STEM CELLS:THE PURPOSE OF THIS RESOURCE IS TO BUILD AND SUPPORT A CRITICAL75N92020C00005 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI N/A, N/A · 2021 to 2024
$2.6M
Functional T cells from iPSCs Using Chimeric Antigen ReceptorsF32HL149605 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HEINZE, DAR · 2019 to 2020
$141k
NHLBI NIH HHS 75N92020C00005NHLBI NIH HHS F32 HL149605
6 · The paper itself

Abstract

A robust method of producing mature T cells from iPSCs is needed to realize their therapeutic potential. NOTCH1 is known to be required for the production of hematopoietic progenitor cells with T cell potential in vivo. Here we identify a critical window during mesodermal differentiation when Notch activation robustly improves access to definitive hematopoietic progenitors with T/NK cell lineage potential. Low-density progenitors on either OP9-hDLL4 feeder cells or hDLL4-coated plates favored T cell maturation into TCRab

Indexed as

Induced Pluripotent Stem CellsMesodermCell DifferentiationCell LineageHumansReceptors, NotchT-LymphocytesReceptors, Notchhematopoietic progenitorhumaniPSCnatural killer cellnotchT cell

Identifiers

PMID36332629
PMCPMC9768581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.